Catalog No.: PC-22091Not For Human Use, Lab Use Only.
EBL-3599 is a novel LpxH inhibitor with IC50 of 3.5 nM for E. coli LpxH enzyme, shows potent activity targeting lipopolysaccharide synthesis in Gram-negative bacteria (K. pneumoniae ATCC 13883, MIC 1 mg/mL).
EBL-3599 is a novel LpxH inhibitor with IC50 of 3.5 nM for E. coli LpxH enzyme, shows potent activity targeting lipopolysaccharide synthesis in Gram-negative bacteria (K. pneumoniae ATCC 13883, MIC 1 mg/mL).
EBL-3599 has potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae.
EBL-3599 has potent in vitro activity against a diverse range of clinical E. coli and K. pneumoniae isolates, irrespective of the resistance genotype.
